# Nicola Giuliani

List of Publications by Year
in descending order



| 177 | 7,129 | 50244<br>46 | 62565<br>80 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 181 | 181 | 181 | 7624 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood, 2001, 98, 3527-3533. | 0.6 | 374 |
| 2 | Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMAâ€"Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465. | 0.8 | 301 |
| 3 | Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 2005, 106, 2472-2483. | 0.6 | 289 |
| 4 | Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood, 2006, 108, 3992-3996. | 0.6 | 279 |
| 5 | Bisphosphonates Stimulate Formation of Osteoblast Precursors and Mineralized Nodules in Murine and Human Bone Marrow Cultures In Vitro and Promote Early Osteoblastogenesis in Young and Aged Mice In Vivo. Bone, 1998, 22, 455-461. | 1.4 | 245 |
| 6 | Human myeloma cells stimulate the receptor activator of nuclear factor-Î°B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood, 2002, 100, 4615-4621. | 0.6 | 241 |
| 7 | The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood, 2007, 110, 334-338. | 0.6 | 241 |
| 8 | IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 2005, 106, 1407-1414. | 0.6 | 187 |
| 9 | Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. Journal of Clinical Oncology, 2010, 28, 800-807. | 0.8 | 166 |
| 10 | Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Experimental Gerontology, 2001, 36, 547-557. | 1.2 | 136 |
| 11 | Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood, 2016, 128, 667-679. | 0.6 | 128 |
| 12 | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2722. | 2.2 | 124 |
| 13 | Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2976-2979. | 1.8 | 117 |
| 14 | Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. European Journal of Endocrinology, 2000, 143, 197-202. | 1.9 | 117 |
| 15 | The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 Î± (HIF-1Î±) activity: involvement in myeloma-induced angiogenesis. Blood, 2007, 110, 4464-4475. | 0.6 | 117 |
| 16 | Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia, 2012, 26, 1391-1401. | 3.3 | 116 |
| 17 | ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell, 2017, 32, 88-100.e6. | 7.7 | 114 |
| 18 | New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-Î°B ligand (RANKL). Experimental Hematology, 2004, 32, 685-691. | 0.2 | 108 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Low bone marrow oxygen tension and hypoxia-inducible factor-1Î± overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells. Leukemia, 2010, 24, 1967-1970. | 3.3 | 107 |
| 20 | Hypoxia-inducible factor (HIF)-1Î± suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia, 2013, 27, 1697-1706. | 3.3 | 104 |
| 21 | Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood, 2003, 102, 638-645. | 0.6 | 103 |
| 22 | Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment. Cancer Research, 2007, 67, 7665-7674. | 0.4 | 102 |
| 23 | NAD+-Metabolizing Ectoenzymes in Remodeling Tumorâ€"Host Interactions: The Human Myeloma Model. Cells, 2015, 4, 520-537. | 1.8 | 99 |
| 24 | Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma. Clinical Cancer Research, 2010, 16, 4188-4197. | 3.2 | 88 |
| 25 | Angiogenesis and Multiple Myeloma. Cancer Microenvironment, 2011, 4, 325-337. | 3.1 | 88 |
| 26 | Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis. Journal of Hematology and Oncology, 2019, 12, 2. | 6.9 | 88 |
| 27 | Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. BioMed Research International, 2015, 2015, 1-13. | 0.9 | 87 |
| 28 | Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell, 2015, 27, 644-657. | 7.7 | 85 |
| 29 | Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma. Molecular Medicine, 2016, 22, 694-704. | 1.9 | 81 |
| 30 | Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood, 2016, 127, 1102-1108. | 0.6 | 78 |
| 31 | Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia, 2004, 18, 628-635. | 3.3 | 75 |
| 32 | Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, 122, 1376-1383. | 0.6 | 74 |
| 33 | Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood, 2008, 112, 2450-2462. | 0.6 | 73 |
| 34 | GPNA inhibits the sodium-independent transport system l for neutral amino acids. Amino Acids, 2017, 49, 1365-1372. | 1.2 | 72 |
| 35 | New Insights into Osteogenic and Chondrogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells and Their Potential Clinical Applications for Bone Regeneration in Pediatric Orthopaedics. Stem Cells International, 2013, 2013, 1-11. | 1.2 | 71 |
| 36 | Elevated Tumor Necrosis Factor-<i>Î±</i>Suppresses TAZ Expression and Impairs Osteogenic Potential of Flk-1<sup>+</sup>Mesenchymal Stem Cells in Patients with Multiple Myeloma. Stem Cells and Development, 2007, 16, 921-930. | 1.1 | 68 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3Î± and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions. Cancer Research, 2008, 68, 6840-6850. | 0.4 | 68 |
| 38 | Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Experimental Hematology, 2013, 41, 387-397.e1. | 0.2 | 65 |
| 39 | Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia, 2005, 19, 2166-2176. | 3.3 | 64 |
| 40 | Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD<sup>+</sup>. OncoImmunology, 2018, 7, e1458809. | 2.1 | 59 |
| 41 | CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica, 2006, 91, 1489-97. | 1.7 | 59 |
| 42 | Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Experimental Hematology, 2010, 38, 141-153. | 0.2 | 57 |
| 43 | Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. Leukemia, 2016, 30, 409-416. | 3.3 | 55 |
| 44 | The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors. Journal of Bone and Mineral Research, 2016, 31, 815-827. | 3.1 | 52 |
| 45 | Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget, 2017, 8, 56598-56611. | 0.8 | 52 |
| 46 | Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia, 2014, 28, 951-954. | 3.3 | 49 |
| 47 | The osteoblastic niche in the context of multiple myeloma. Annals of the New York Academy of Sciences, 2015, 1335, 45-62. | 1.8 | 49 |
| 48 | Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia, 2013, 27, 451-463. | 3.3 | 48 |
| 49 | Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences, 2015, 1335, 10-22. | 1.8 | 47 |
| 50 | Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myeloma. Leukemia and Lymphoma, 2007, 48, 2323-2329. | 0.6 | 46 |
| 51 | Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood, 2006, 107, 841-842. | 0.6 | 45 |
| 52 | Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: Identification of potential therapeutic targets. Experimental Hematology, 2009, 37, 879-886. | 0.2 | 43 |
| 53 | Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight, 2020, 5, . | 2.3 | 43 |
| 54 | Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomyin vivoand decrease its release in human osteoblastic cellsin vitro. Clinical Endocrinology, 1999, 51, 801-807. | 1.2 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood, 2021, 137, 3027-3036. | 0.6 | 40 |
| 56 | HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia, 2011, 25, 527-537. | 3.3 | 39 |
| 57 | Constitutive expression of IL-12RÎ²2 on human multiple myeloma cells delineates a novel therapeutic target. Blood, 2008, 112, 750-759. | 0.6 | 38 |
| 58 | OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?. Clinical Rheumatology, 2005, 24, 296-300. | 1.0 | 37 |
| 59 | <i>IL21R</i> expressing CD14 <sup>+</sup> CD16 <sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica, 2017, 102, 773-784. | 1.7 | 36 |
| 60 | Impact of XIAP protein levels on the survival of myeloma cells. Haematologica, 2009, 94, 87-93. | 1.7 | 34 |
| 61 | Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy. Frontiers in Immunology, 2018, 9, 2467. | 2.2 | 31 |
| 62 | Gene array profile identifies collagen type XV as a novel human osteoblastâ€secreted matrix protein. Journal of Cellular Physiology, 2009, 220, 401-409. | 2.0 | 30 |
| 63 | A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay. Vaccines, 2021, 9, 389. | 2.1 | 30 |
| 64 | Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. Leukemia, 2016, 30, 2351-2363. | 3.3 | 29 |
| 65 | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents. Cells, 2019, 8, 1632. | 1.8 | 28 |
| 66 | Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. Journal of Hematology and Oncology, 2019, 12, 4. | 6.9 | 27 |
| 67 | Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget, 2017, 8, 53053-53067. | 0.8 | 27 |
| 68 | CD38 and bone marrow microenvironment. Frontiers in Bioscience - Landmark, 2014, 19, 152. | 3.0 | 26 |
| 69 | Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567. | 15.2 | 26 |
| 70 | Novel targets for the treatment of relapsing multiple myeloma. Expert Review of Hematology, 2019, 12, 481-496. | 1.0 | 25 |
| 71 | Angiogenic Switch in Multiple Myeloma. Hematology, 2004, 9, 377-381. | 0.7 | 24 |
| 72 | Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. Cancers, 2019, 11, 321. | 1.7 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica, 2004, 89, 1118-23. | 1.7 | 23 |
| 74 | Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability. Cancers, 2020, 12, 3267. | 1.7 | 22 |
| 75 | Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial. Blood, 2020, 136, 38-40. | 0.6 | 22 |
| 76 | Role of Galectins in Multiple Myeloma. International Journal of Molecular Sciences, 2017, 18, 2740. | 1.8 | 21 |
| 77 | Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets. Cells, 2021, 10, 1360. | 1.8 | 19 |
| 78 | Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells. Haematologica, 2005, 90, 275-8. | 1.7 | 19 |
| 79 | The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma. Expert Opinion on Therapeutic Targets, 2017, 21, 231-234. | 1.5 | 18 |
| 80 | CD14 + CD16 + monocytes are involved in daratumumabâ€mediated myeloma cells killing and in antiâ€CD47 therapeutic strategy. British Journal of Haematology, 2020, 190, 430-436. | 1.2 | 18 |
| 81 | Do human myeloma cells directly produce basic FGF?. Blood, 2003, 102, 3071-3073. | 0.6 | 17 |
| 82 | Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells. Clinical Cancer Research, 2011, 17, 6963-6970. | 3.2 | 17 |
| 83 | Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL. Blood, 2013, 122, 2641-2653. | 0.6 | 17 |
| 84 | Predicting and Optimizing Microswimmer Performance from the Hydrodynamics of Its Components: The Relevance of Interactions. Soft Robotics, 2018, 5, 410-424. | 4.6 | 17 |
| 85 | The Circular Life of Human CD38: From Basic Science to Clinics and Back. Molecules, 2020, 25, 4844. | 1.7 | 17 |
| 86 | Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide. Blood Advances, 2017, 1, 2166-2175. | 2.5 | 16 |
| 87 | First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica, 2020, 105, 1074-1080. | 1.7 | 16 |
| 88 | Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells. Blood, 2015, 126, 1849-1849. | 0.6 | 16 |
| 89 | Ï€-BEM: A flexible parallel implementation for adaptive, geometry aware, and high order boundary element methods. Advances in Engineering Software, 2018, 121, 39-58. | 1.8 | 15 |
| 90 | The Proteasome and Myeloma-Associated Bone Disease. Calcified Tissue International, 2018, 102, 210-226. | 1.5 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression. Cancers, 2021, 13, 164. | 1.7 | 15 |
| 92 | Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia, 2014, 28, 2094-2097. | 3.3 | 14 |
| 93 | Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. International Journal of Hematology, 2017, 105, 104-108. | 0.7 | 14 |
| 94 | deal2lkit: A toolkit library for high performance programming in deal.II. SoftwareX, 2018, 7, 318-327. | 1.2 | 13 |
| 95 | Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy. Journal of Hematology and Oncology, 2020, 13, 89. | 6.9 | 13 |
| 96 | Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 3022. | 1.0 | 12 |
| 97 | PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients. Frontiers in Immunology, 2020, 11, 613007. | 2.2 | 12 |
| 98 | Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Frontiers in Oncology, 2021, 11, 684561. | 1.3 | 12 |
| 99 | Hypoxia and Hypoxia Inducible Factor (HIF)-1Î± in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment.. Blood, 2008, 112, 1687-1687. | 0.6 | 12 |
| 100 | The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1Â inhibition in myeloma cells. Haematologica, 2016, 101, e107-e110. | 1.7 | 11 |
| 101 | Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. Cancers, 2019, 11, 261. | 1.7 | 11 |
| 102 | The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38. Immunology Letters, 2019, 205, 65-70. | 1.1 | 11 |
| 103 | Biology and Treatment of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2006, 12, 81-86. | 2.0 | 10 |
| 104 | Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis. Journal of Hematology and Oncology, 2018, 11, 123. | 6.9 | 10 |
| 105 | Possible targets to treat myeloma-related osteoclastogenesis. Expert Review of Hematology, 2018, 11, 325-336. | 1.0 | 9 |
| 106 | [18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma. Frontiers in Oncology, 2021, 11, 760732. | 1.3 | 9 |
| 107 | Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia, 2010, 24, 1368-1370. | 3.3 | 8 |
| 108 | FEM SUPG stabilisation of mixed isoparametric BEMs: Application to linearised free surface flows. Engineering Analysis With Boundary Elements, 2015, 59, 8-22. | 2.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Haploidentical hematopoietic stem cell transplantation in adults using the Î±Î²TCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells. Bone Marrow Transplantation, 2019, 54, 698-702. | 1.3 | 8 |
| 110 | The transcriptomic profile of CD138<sup>+</sup> cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. Haematologica, 2019, 104, e465-e469. | 1.7 | 8 |
| 111 | Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. Frontiers in Immunology, 2020, 11, 573156. | 2.2 | 8 |
| 112 | Angiopoietin-1 and Myeloma-Induced Angiogenesis. Leukemia and Lymphoma, 2005, 46, 29-33. | 0.6 | 7 |
| 113 | The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Experimental Hematology, 2011, 39, 55-65. | 0.2 | 7 |
| 114 | Editorial: Immunotherapy in Multiple Myeloma. Frontiers in Immunology, 2019, 10, 1945. | 2.2 | 7 |
| 115 | Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies. Journal of Clinical Medicine, 2020, 9, 2864. | 1.0 | 7 |
| 116 | Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. Cancers, 2020, 12, 1332. | 1.7 | 7 |
| 117 | Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer Journal, 2021, 11, 73. | 2.8 | 7 |
| 118 | Functional Consequences of Low Activity of Transport System A for Neutral Amino Acids in Human Bone Marrow Mesenchymal Stem Cells. International Journal of Molecular Sciences, 2020, 21, 1899. | 1.8 | 6 |
| 119 | How<i>Euglena gracilis</i>swims: Flow field reconstruction and analysis. Physical Review E, 2021, 103, 023102. | 0.8 | 6 |
| 120 | Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effects of IL-3 in Myeloma,. Blood, 2011, 118, 3933-3933. | 0.6 | 6 |
| 121 | Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. Blood, 2012, 120, 446-446. | 0.6 | 6 |
| 122 | Targeting Pathways Mediating Bone Disease. Current Pharmaceutical Biotechnology, 2006, 7, 423-429. | 0.9 | 5 |
| 123 | Extended and reduced POG dynamic model of an automatic corking machine for threaded plastic caps. Mechatronics, 2014, 24, 1-11. | 2.0 | 5 |
| 124 | Bone marrow Dikkopfâ€1 levels are a new independent risk factor for progression in patients with smouldering myeloma. British Journal of Haematology, 2018, 183, 812-815. | 1.2 | 5 |
| 125 | A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis. Case Reports in Hematology, 2018, 2018, 1-5. | 0.3 | 5 |
| 126 | Assessment of the interlaboratory variability and robustness of <i>JAK2</i>V617F mutation assays: A study involving a consortium of 19 Italian laboratories. Oncotarget, 2017, 8, 32608-32617. | 0.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A. Blood, 2013, 122, 3101-3101. | 0.6 | 5 |
| 128 | Bisphosphonates in Multiple Myeloma: Preclinical and Clinical Data. Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 113-121. | 1.3 | 4 |
| 129 | Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?. Acta Haematologica, 2021, 144, 302-307. | 0.7 | 4 |
| 130 | Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood, 2018, 132, 1798-1798. | 0.6 | 4 |
| 131 | Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients. Blood, 2012, 120, 3978-3978. | 0.6 | 3 |
| 132 | Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1238-1241. | 0.6 | 2 |
| 133 | The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes. Applied Sciences (Switzerland), 2021, 11, 4642. | 1.3 | 2 |
| 134 | Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?. Transplant International, 2021, 34, 2442-2458. | 0.8 | 2 |
| 135 | Proteasome Stress Causes Apoptotic Sensitivity of Multiple Myeloma Cells to Proteasome Inhibition. Blood, 2008, 112, 247-247. | 0.6 | 2 |
| 136 | In Vitro and In Vivo Evidences of Osteocyte Involvement In Myeloma-Induced Osteolysis. Blood, 2010, 116, 131-131. | 0.6 | 2 |
| 137 | Hypoxia-Inducible Factor (HIF)-1Î± Is a Therapeutic Target in Myeloma-Induced Angiogenesis. Blood, 2011, 118, 3927-3927. | 0.6 | 2 |
| 138 | Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients. Blood, 2016, 128, 4647-4647. | 0.6 | 2 |
| 139 | Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2016, 128, 5697-5697. | 0.6 | 2 |
| 140 | Dynamic modeling and control of a new automatic corking machine for threaded plastic caps. , 2011, , . | | 1 |
| 141 | Neurofibromatosis type I and multiple myeloma coexistence: A possible link?. Hematology Reports, 2018, 10, 7457. | 0.3 | 1 |
| 142 | Oncolytic Virotherapy and Microenvironment in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 2259. | 1.8 | 1 |
| 143 | Macrophage Inflammatory Protein (MIP)-3Î±/CCL20 and Its Receptor CCR6 Are Overexpressed in the Bone Microenvironment and Involved in Osteoclast Formation in Multiple Myeloma Patients.. Blood, 2007, 110, 3510-3510. | 0.6 | 1 |
| 144 | Oxygen Tension in the Bone Marrow (BM) of Patients with Malignant and Indolent Monoclonal Gammopathy: Role of Hypoxia and Hypoxia-Inducible Factor (HIF)-1Î± in the Regulation of Gene Expression and Pro-Angiogenic Profiles of CD138+ Cells.. Blood, 2009, 114, 422-422. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and RANKL/OPG Ratio In Myeloma Microenvironment Targeting the Expression of Adhesion Molecules. Blood, 2010, 116, 448-448. | 0.6 | 1 |
| 146 | Myeloma-Induced Osteocyte Death Was Blunted By Proteasome Inhibitors Through The Modulation Of Autophagy. Blood, 2013, 122, 3096-3096. | 0.6 | 1 |
| 147 | Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity. Blood, 2015, 126, 2959-2959. | 0.6 | 1 |
| 148 | Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells. Blood, 2016, 128, 4422-4422. | 0.6 | 1 |
| 149 | Activation of Non-Canonical Wnt Pathway in Human Mesenchymal Cells Affects Osteogenic Differentiation: A Potential Target in Multiple Myeloma Microenvironment. Blood, 2008, 112, 2742-2742. | 0.6 | 1 |
| 150 | TBK1/IkkÎµ Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo. Blood, 2018, 132, 4504-4504. | 0.6 | 1 |
| 151 | Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts. Blood, 2020, 136, 20-21. | 0.6 | 1 |
| 152 | Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulinâ€dependent diabetes. Journal of Internal Medicine, 1998, 243, 43-48. | 2.7 | 0 |
| 153 | Myeloma and osteoclast relationship. , 2015, , 491-500. | | 0 |
| 154 | BlackNUFFT: Modular customizable black box hybrid parallelization of type 3 NUFFT in 3D. Computer Physics Communications, 2019, 235, 324-335. | 3.0 | 0 |
| 155 | Immunohistologic Identification and Quantification of Human Bone Marrow Hematopoietic Stem Cells.. Blood, 2005, 106, 2301-2301. | 0.6 | 0 |
| 156 | HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis. Blood, 2008, 112, 2743-2743. | 0.6 | 0 |
| 157 | Bone Microenvironment Cells Show a Different Pattern of Gene Expression Profiling in Relationship with the Presence of Osteolytic Bone Lesions in Multiple Myeloma Patients. Blood, 2008, 112, 2740-2740. | 0.6 | 0 |
| 158 | Increased Osteocyte Apoptosis in Multiple Myeloma Patients: A Potential Role in Bone Remodeling Alterations Related to Osteolytic Bone Lesions.. Blood, 2009, 114, 830-830. | 0.6 | 0 |
| 159 | Are the Myeloma Bone Microevironment Cells Tumoral or Not?.. Blood, 2009, 114, 1816-1816. | 0.6 | 0 |
| 160 | Myeloma Cells Inhibit the Non-Canonical Wnt Co-Receptor Ror2 in Human Mesenchymal/Osteoprogenitor Cells: Effect of Wnt5a/Ror2 Pathway Activation On MM-Induced Impairment of the Osteogenic Differentiation Process.. Blood, 2009, 114, 741-741. | 0.6 | 0 |
| 161 | Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib.. Blood, 2009, 114, 1837-1837. | 0.6 | 0 |
| 162 | HOXB7 Is Critically Involved in Multiple Myeloma-Induced Angiogenic Switch.. Blood, 2009, 114, 125-125. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Mechanisms Involved in Osteoblast Suppression in Multiple Myeloma. , 2010, , 231-242. | | 0 |
| 164 | Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma. Blood, 2010, 116, 4059-4059. | 0.6 | 0 |
| 165 | The Activation of Wnt5a-Mediated Non Canonical Wnt Signaling in Human Bone Marrow Osteoprogenitor Cells Increases Osteoblastogenesis and Counterbalances the Inhibitory Effect of Myeloma Cells on Ror2/FZD5 Expression,. Blood, 2011, 118, 3928-3928. | 0.6 | 0 |
| 166 | Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo.. Blood, 2012, 120, 2947-2947. | 0.6 | 0 |
| 167 | CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment. Blood, 2012, 120, 444-444. | 0.6 | 0 |
| 168 | Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance. Blood, 2012, 120, 1811-1811. | 0.6 | 0 |
| 169 | Relationship Between Presence Of Osteolytic Lesions, Cytogenetic Features and Bone Marrow Levels Of Cytokines and Chemokines In Multiple Myeloma Patients: Role Of Chemokine (C-C motif) Ligand 20. Blood, 2013, 122, 3110-3110. | 0.6 | 0 |
| 170 | The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4. Blood, 2015, 126, 5315-5315. | 0.6 | 0 |
| 171 | ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. Blood, 2016, 128, 359-359. | 0.6 | 0 |
| 172 | Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML. Blood, 2016, 128, 4302-4302. | 0.6 | 0 |
| 173 | Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively. Blood, 2016, 128, 4464-4464. | 0.6 | 0 |
| 174 | Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. Blood, 2018, 132, 2023-2023. | 0.6 | 0 |
| 175 | Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients. Blood, 2018, 132, 3183-3183. | 0.6 | 0 |
| 176 | Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease. Blood, 2019, 134, 4339-4339. | 0.6 | 0 |
| 177 | Microrom: An efficient and accurate reduced order method to solve many-query problems in micro-motility Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â. ESAIM: Mathematical Modelling and Numerical Analysis, 0, , . | 0.8 | 0 |